The global pain management market was valued at $79.4 billion in 2021 and is projected to grow to $120.7 billion by 2027, with a compound annual growth rate (CAGR) of 7.39%.

Sparsentan is a small molecule drug that targets AT1R x ETA and has been approved for use in the treatment of a variety of therapeutic areas.

Zanubrutinib is a small molecule drug that targets the BTK enzyme and is approved for use in various therapeutic areas including neoplasms.

The drug VVD-130037 is a small molecule drug developed to target the KEAP1 x Nrf2 pathways in the treatment of neoplasms.

Risperidone is a small molecule drug that acts on the 5-HT2A and D2 receptors.

Suzetrigine is a small molecule drug developed by Vertex Pharmaceuticals, Inc. It is designed to target the Nav1.8 channel.

The small molecule drug, TYRA-300, developed by Tyra Biosciences, Inc., targets FGFR3 and falls under the category of rare pediatric disease.

Pirtobrutinib is a small molecule drug developed by Redx Pharma Plc, targeting BTK C481S. Pirtobrutinib has received its first approval in the United States.

Sotorasib is an oral medication developed to target a specific mutation in the KRAS gene, known as KRAS G12C, which is implicated in various cancers.

PLX-4545 is a molecular glue drug developed by Plexium, Inc. The drug targets IKZF2 and is intended for the treatment of neoplasms.

Omaveloxolone is a small molecule drug developed by Reata Pharmaceuticals, Inc. that targets the Nrf2 protein.

Palbociclib was first approved in the United States in February 2015 and has since been approved in other countries around the world.